美泊利珠单抗与度普利尤单抗在嗜酸性表型COPD中减少急性加重无显著差异:匹配调整间接比较
本研究采用匹配调整间接比较(MAIC)方法,比较美泊利珠单抗(3项3期随机安慰剂对照试验)与度普利尤单抗(2项试验)在嗜酸性表型COPD患者中的疗效。结果显示,两者在减少中重度急性加重年化率及改善健康相关生活质量(SGRQ-C)方面均无统计学显著差异。
要点
- MAIC显示美泊利珠单抗与度普利尤单抗减少中重度急性加重无显著差异。
- 两种生物制剂对SGRQ-C评分改善亦无统计学显著差异。
- 结果支持在嗜酸性表型COPD中两者疗效相当,但需结合患者特征选择。
核心结论
- 在嗜酸性表型COPD患者中,美泊利珠单抗与度普利尤单抗在减少中重度急性加重和改善生活质量方面无统计学显著差异。
研究设计与样本
- 采用匹配调整间接比较(MAIC),汇总美泊利珠单抗的3项3期随机安慰剂对照试验(METREX、METREO、MATINEE)与度普利尤单抗的2项试验(BOREAS、NOTUS)的疗效数据。
- 使用倾向评分方法对美泊利珠单抗试验的个体患者数据重新加权,以匹配度普利尤单抗试验人群的基线特征。
- 纳入美泊利珠单抗试验中符合度普利尤单抗试验更严格入选标准的患者:筛查时血嗜酸性粒细胞计数≥300 cells/μL、mMRC呼吸困难分级≥2、中重度气流受限、慢性支气管炎(由研究者评估或SGRQ-C定义)。
主要发现
- 中重度急性加重年化率降低无统计学显著差异:研究者评估慢性支气管炎定义的风险比0.91(95% CI 0.60-1.37),SGRQ-C慢性支气管炎定义的风险比1.13(95% CI 0.80-1.58)。
- SGRQ-C评分变化无统计学显著差异。
关键数值与推荐
- 中重度急性加重年化率风险比:研究者评估慢性支气管炎定义0.91(95% CI 0.60-1.37),SGRQ-C慢性支气管炎定义1.13(95% CI 0.80-1.58)。
- SGRQ-C评分变化无统计学显著差异。
临床怎么用
- 对于嗜酸性表型COPD患者,美泊利珠单抗和度普利尤单抗在减少急性加重和改善生活质量方面疗效相当,选择时可综合考虑其他因素。
局限性
- 本研究为间接比较,可能存在未测量的混杂因素。
- MAIC仅纳入符合度普利尤单抗试验入选标准的美泊利珠单抗试验患者,可能限制结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mepolizumab and dupilumab are monoclonal antibodies targeting type 2 inflammation that are both approved as add-on maintenance treatment in patients with inadequately controlled COPD and an eosinophilic phenotype. RESEARCH QUESTION: What is the comparative efficacy of mepolizumab and dupilumab in reducing the risk of exacerbations and improving health-related quality of life in patients with COPD and an eosinophilic phenotype? STUDY DESIGN AND METHODS: This study used a robust matching-adjusted indirect comparison (MAIC) approach to compare pooled efficacy data from 3 phase 3 randomized, placebo-controlled COPD trials of mepolizumab (METREX, METREO, and MATINEE) with 2 trials of dupilumab (BOREAS and NOTUS). An indirect comparison was performed using MAIC, reweighting individual patient data from mepolizumab trials using propensity score-based methods to match the aggregate baseline characteristics of the dupilumab trial populations. To match the more restrictive eligibility criteria of the dupilumab trials, patients from the mepolizumab studies were included in this MAIC if they showed blood eosinophil counts of ≥ 300 cells/μL at screening, modified Medical Research Council scale dyspnea grade ≥ 2, moderate-to-severe airflow limitation, and chronic bronchitis (CB; defined by investigator assessment or St. George's Respiratory Questionnaire for COPD [SGRQ-C]). Outcomes included rate or risk of exacerbations and health-related quality of life (SGRQ-C). RESULTS: No statistically significant differences were observed in the reduction of the annualized rate of moderate to severe exacerbations (rate ratio, 0.91 [95% CI, 0.60-1.37] using investigator-assessed CB and 1.13 [95% CI, 0.80-1.58] using the SGRQ-C CB definition). No statistically significant differences were observed in SGRQ-C changes. INTERPRETATION: Our results from this MAIC study showed no statistically significant differences between mepolizumab and dupilumab in the magnitude of effect in reducing moderate to severe exacerbations and improving health-related quality-of-life outcomes.
引用
- Bourbeau J, Min J, Kolterer S, et al. Mepolizumab and Dupilumab Show No Significant Difference in Reducing Exacerbations in Patients With COPD and an Eosinophilic Phenotype: Matching-Adjusted Indirect Treatment Comparison. Chest. 2026. PMID: 42617837. doi:10.1016/j.chest.2026.07.5242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。